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A B S T R A C T
The introduction of therapeutics targeting specific tumor-promoting oncogenic or non-oncogenic signaling
pathways has revolutionized cancer treatment. Mechanistic (previously mammalian) target of rapamycin
(mTOR), a highly conserved Ser/Thr kinase, is a central hub of the phosphatidylinositol 3-kinase (PI3K)/Akt/
mTOR network, one of the most frequently deregulated signaling pathways in cancer, that makes it an attractive
target for therapy. Numerous mTOR inhibitors have progressed to clinical trials and two of them have been
officially approved as anticancer therapeutics. However, mTOR-targeting drugs have met with a very limited
success in cancer patients. Frequently, the primary impediment to a successful targeted therapy in cancer is drug-
resistance, either from the very beginning of the therapy (innate resistance) or after an initial response and upon
repeated drug treatment (evasive or acquired resistance). Drug-resistance leads to treatment failure and relapse/
progression of the disease. Resistance to mTOR inhibitors depends, among other reasons, on activation/deac-
tivation of several signaling pathways, included those regulated by glycogen synthase kinase-3 (GSK3), a protein
that targets a vast number of substrates in its repertoire, thereby orchestrating many processes that include cell
proliferation and survival, metabolism, differentiation, and stemness. A detailed knowledge of the rewiring of
signaling pathways triggered by exposure to mTOR inhibitors is critical to our understanding of the con-
sequences such perturbations cause in tumors, including the emergence of drug-resistant cells.
Here, we provide the reader with an updated overview of intricate circuitries that connect mTOR and GSK3
and we relate them to the efficacy (or lack of efficacy) of mTOR inhibitors in cancer cells.
1. Introduction
For many decades, the mainstays of anticancer therapy have been
surgery, radiation, and chemotherapy. Targeted therapy of cancer has
become an exciting field for both the academics and the pharmaceutical
industry since the approval of imatinib, a tyrosine kinase inhibitor, for
treatment of newly diagnosed chronic myelogenous leukemia (CML) in
2002 [1]. While imatinib and its derivatives have revolutionized the
therapy of CML and changed the natural history of the disorder, most of
the agents targeting cancer cell signaling pathways have met with an
extremely limited success, due to a number of reasons that include
drug-resistance of neoplastic cells [2]. Cancer cells can develop drug-
resistance due to either intrinsic factors (activation of alternative sig-
naling pathways, gene mutations, epigenetic alterations etc.) or
extrinsic factors (hypoxia, pH, hormones/cytokines secreted by the
tumor microenvironment) [3]. In particular, the tumor spatial and
temporal heterogeneity as well as the mutational load of cancers have
been directly associated with the emergence of evasive resistance to
targeted therapies [4–6].
The phosphatidylinositol-3 kinase (PI3K)/Akt/mechanistic target of
rapamycin (mTOR) signaling network is frequently activated in an
aberrant manner in most of human cancers, where it controls many
processes essential for tumor growth and survival [7–9]. A large array
of small molecule inhibitors of the PI3K/Akt/mTOR signaling pathway
have been studied in preclinical models of human cancer, where their
proved their efficacy as antineoplastic agents. However, only a few of
these inhibitors are currently approved for cancer treatment, as clinical
trials of drugs targeting PI3K/Akt/mTOR have usually provided
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disappointing results [10,11]. Indeed, despite exciting preclinical
findings, drug-resistance remains a primary hindrance in the clinic.
Failure of the PI3K/Akt/mTOR inhibitors to act as effective anticancer
molecules in humans is due to several reasons, which may also depend
on activation/deactivation of other signaling pathways, including those
regulated by glycogen synthase kinase-3 (GSK3). Here, we will discuss
the most recent advances in understanding how GSK3 signals crosstalk
with mTOR and impact on the efficacy of inhibitors that target mTOR.
2. GSK3
GSK3 is a serine/threonine protein kinase, ubiquitously expressed
throughout vertebrates, that is capable of phosphorylating over a
hundred of substrates, although only a small fraction of these have been
convincingly validated in physiological cell systems [12,13]. GSK3
exists in mammalian cells as GSK3α (51 kDa) and GSK3β (47 kDa)
isoforms (or, more correctly, paralogs, as they are homologous proteins
derived from different genes), that are both constitutively active.
GSK3α and GSK3β are encoded by separate genes (named GSK3A and
GSK3B in humans) located at 19q13.2 and 3q13.3, respectively. The
two isoforms share a highly conserved (98%) catalytic domain while
differing at both termini [14]. Therefore, their overall homology is
about 85%.
GSK3α activity is mainly regulated via phosphorylation at Ser21
(inhibition) and Tyr279 (activation), whereas in GSK3β the corre-
sponding amino acidic residues are Ser9 and Tyr216 [15,16]. The
phosphorylated Ser residues of GSK3 act as pseudosubstrates that block
the substrate binding site and inhibit the enzyme activity [17]. GSK-
inactivating kinases include Akt, 90-kDa ribosomal S6 kinase (p90RSK),
70-kDa ribosomal S6 kinase 1 (p70S6K1), and protein kinase A (PKA)
[18]. In contrast, the two tyrosine residues are believed to be autop-
hosphorylated by GSK3 itself, although there are reports showing that
other kinases could be involved, including mitogen-activated protein
kinase kinase (MEK) 1 [19,20]. Nevertheless, regulation of GSK3 ac-
tivity could also depend on either intracellular localization or interac-
tions with other proteins [18].
For the purposes of this review, it is important to point out that a
fraction of GSK3 localizes to the nucleus of both healthy and cancer
cells [21–24]. Consistently, some GSK3 substrates (e.g. c-Myc, Snail
[25,26]) are nuclear transcription factors.
Both GSK3 paralogs are detected in most human tissues, however
their relative abundance varies depending on the cell type being studied
[12,27,28]. Moreover, the two paralogs have specific substrates, hence
loss of one paralog cannot be compensated for by the other [18], as also
demonstrated by the fact that mice with a homozygous deletion of
Gsk3a are viable despite defects in neuronal development and meta-
bolism. These mice display improved insulin sensitivity, increased he-
patic glycogen accumulation, and diminished adiposity. In contrast,
homozygous knockout of Gsk3b is embryonic-lethal, due to liver
apoptosis or a cardiac patterning defect [18]. However, in some cases
(Wnt/β-catenin signaling for example) both isozymes play similar roles
[29].
As it names implies, GSK3 was originally discovered as the protein
kinase that phosphorylates glycogen synthase, i.e. the rate-limiting
enzyme in glycogen synthesis [30]. However, it is now clear that GSK3
is critically involved in several signaling pathways that control gene
transcription, nutrient sensing, mitochondrial function, autophagy, and
apoptosis [28]. GSK3 acts as negative regulator of Wnt/β-catenin, Sonic
Hedgehog, tyrosine kinase receptor, and G-protein-coupled receptor
signaling networks [14]. As to Wnt/β-catenin signaling, GSK3β is part
of an inhibitory degradative multiprotein complex that includes ade-
nomatous polyposis coli (APC), axis inhibition protein 2 (AXIN2),
casein kinase 1 (CK1), and β-catenin itself [31].
Importantly, both GSK3 isoforms preferentially phosphorylate sub-
strates that have already been phosphorylated by other protein kinases
or “priming kinases”. Priming kinases include CK1, extracellular signal-
regulated kinase (ERK), p38 mitogen-activated protein kinase
(p38MAPK), c-Jun N-terminal kinase (JNK), and 5′-adenosine mono-
phosphate-activated protein kinase (AMPK) [32].
Aberrant regulation of GSK3 activity has been reported in several
human disorders, including type 2 diabetes, atherosclerosis,
Alzheimer's disease, Parkinson's disease, mood disorders, and cancer
[33–35], as well as during aging [36]. Regarding cancer, GSK3 was
initially considered as a potential tumor suppressor due to its capacity
to phosphorylate pro-oncogenic molecules such as c-Jun [37], β-catenin
[38], cyclin D1 [39], and c-Myc [25]. This may be true for some skin
[40], oral [41], lung [42], and breast cancers [43]. In particular, the
phosphorylation of some GSK3 substrates critically involved in the
control of cell proliferation or survival, creates a “phosphodegron”
which is recognized by specific E3 ubiquitin ligases resulting in tar-
geting of the phosphorylated proteins for degradation by the protea-
some [44].
However, over the last 15 years an ever increasing body of evidence
has emerged indicating that GSK3 could act as a positive regulator of
neoplastic cell proliferation and survival [28,35]. Indeed, GSK3 reg-
ulates cancer cell stemness, invasion, proliferation, survival, metabo-
lism, and treatment-resistance also via its effects on microRNAs ex-
pression [45–48]. The tumor promoter role of GSK3 is substantiated by
the elevated expression levels of the kinase detected in some types of
tumors and/or by the antiproliferative effects of GSK3 inhibitors. The
cancer types include colorectal [49], pancreatic [50], renal [51], and
ovarian [52] carcinoma, as well as glioblastoma multiforme (GBM,
[53]), mixed lineage acute leukemia [54], and CML [55].
Overall, the GSK3 paralog that is mostly involved in cancer (either
as tumor suppressor or tumor promoter) is the β one [20]. However,
GSK3α plays an important role as tumor promoter in acute leukemia
development from myelodysplastic syndrome [56] and as a tumor
suppressor in oral cancer [41].
3. PI3K/Akt/mTOR signaling
Phosphatidylinositol 3-kinase (PI3K) is a family of inositol lipid
kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate
(PIP2), thereby converting it to phosphatidylinositol 3,4,5- tripho-
sphate (PIP3). PIP3 generated at the plasma membrane acts as a
docking site for both phosphoinositide-dependent kinase 1 (PDK1) and
Akt. The interaction between PDK1 and Akt results in Akt being phos-
phorylated at Thr308 [57]. However, PIP3 is important also for the
activation of the mTOR complex 2 (mTORC2) [58], that phosphorylates
Akt at Ser473 [59]. Phosphorylated Akt then activates its downstream
effector, mechanistic target of rapamycin (mTOR) complex 1
(mTORC1) mainly via tuberous sclerosis 1/2 complex (TSC1/TSC2) and
the small GTP-ase Ras-homolog enriched in brain (Rheb) [60].
mTORC1 and mTORC2 control many functions that are of fundamental
importance for cancer cell pathophysiology, including mRNA transla-
tion, ribosome biogenesis, glycolysis, purine and pyrimidine synthesis,
lipid synthesis, autophagy, angiogenesis, cell motility, and cytoskeletal
organization [61,62]. GSK3 was the first reported substrate of Akt that
exerts an inhibitory phosphorylation by targeting an amino-terminal
motif conserved in both GSK3α (Ser21) and GSK3β (Ser9) [63]. GSK3
controls a large, functionally diverse array of downstream substrates,
most of which are either degraded or inhibited upon phosphorylation
by GSK3 [18]. Therefore, Akt upregulates these targets indirectly via
the inhibition of GSK3. These substrates include, among the others, the
prosurvival B-cell lymphoma 2 (Bcl-2) family member myeloid cell
leukemia 1 (Mcl-1) [64] or transcription factors such c-Myc [65], sterol
regulatory element binding protein 1c (SREBP1c) [66], nuclear factor
E2-related factor 2 (Nfr2) [67], Hypoxia-inducible transcription factor
1α (Hif-1α) [68], and forkhead/winged helix family k1 (Foxk1) [69].
Several targets of GSK3 are positively involved in the control of neo-
plastic cell proliferation, survival, and metabolism. Therefore, GSK3
switch-off due to aberrantly activated oncogenic Akt signaling [10]
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provides an advantage to cancer cells.
4. GSK3 inhibitors
Being a kinase at the crossroads of numerous cell growth and me-
tabolic signaling networks, GSK3 is an attractive therapeutic target in
cancer.
The discovery of lithium as a direct and indirect inhibitor of GSK3-
related pathways was a major breakthrough in this field [70]. However,
over the years several synthetic GSK3 inhibitors have been disclosed,
with most of the drugs being ATP-competitive molecules. Early in-
hibitors (SB216763, for example) were not selective for GSK3, as they
also targeted cyclin-dependent kinases (CDK)s, given that CDKs share
33% amino acid identity with GSK3. Subsequently, more specific and
potent drugs, such as AR-A014418, CHIR99021, and the closely related
compounds, CHIR98023 and CHIR98014, have been released [71].
Usually, compounds targeting GSK3 inhibit both GSK3α and GSK3β
with almost equal potency [71]. Nevertheless, selective inhibitors of
GSK3α and GSK3β have been described, such as compound 27 and
BRD0705 (that target GSK3α [72,73]) or TWS199 (that targets GSK3β
[74]).
In contrast, tideglusib (NP031112) is an oral irreversible, non-
competitive GSK3β-selective inhibitor that has been tested in patients
with neurological disorders, such as Alzheimer's disease and supra-
nuclear palsy [71].
Although a large number of GSK3 inhibitors have entered clinical
trials [75], only a few of these studies have been published. LY2090314,
an ATP-competitive intravenous GSK3α/β inhibitor [76], has been
tested in a phase II clinical trial in patients with acute myelogenous
leukemia (AML). Although the drug displayed an acceptable safety
profile, the clinical benefit was extremely limited as monotherapy [77].
It has also been used for treating advanced cancers in combination with
Pemetrexed and carboplatin, however the authors did not report any
therapeutic benefits [78].
In general, the development of GSK3 inhibitors in cancer patients
has traditionally been considered extremely challenging because of the
very large number of functionally diverse GSK3 substrates, whose tar-
geting could lead to the potential disruption of cellular processes of
vital importance for healthy cells. However, the long-term administra-
tion of lithium for treatment of bipolar disorder suggests that GSK3
inhibition may be tolerated and be effective for many years [79]. Also
tideglusib and LY2090314 seem to be quite well-tolerated [20].
5. mTOR inhibitors
mTOR was originally discovered as the target of the antibiotic ra-
pamycin [80]. Three classes of mTOR inhibitors have been developed
and tested as antineoplastic therapeutics in many preclinical studies
and clinical trials. The classes comprise: 1) allosteric mTOR inhibitors,
which include rapamycin and its derivatives or rapalogs (RAD001/
everolimus, CCI-779/temsirolimus). Rapamycin and rapalogs are con-
sidered to be selective mTORC1 inhibitors. However, long-term treat-
ment of cancer cells with this class of drugs frequently leads also to
inhibition of mTORC2 [2]. 2) ATP-competitive dual PI3K/mTOR in-
hibitors that target mTORC1, mTORC2, and PI3K. 3) ATP-competitive
mTOR kinase inhibitors (TORKIs) that inhibit both mTORC1 and
mTORC2, but spare PI3K (Fig. 1). Of these drugs, only the two rapalogs,
everolimus and temsirolimus, have been approved by the Food and
Drug Administration (FDA) and the European Medicines Agency (EMA)
for treatment of some types of refractory/relapsed/advanced cancer
[81] (Fig. 2).
6. Crosstalks between GSK3 and mTORC1/mTORC2 signaling
GSK3 and mTORC1 are connected together via intricate and not
well-defined circuitries that are only now beginning to be unraveled.
Evidence indicates the possibility that GSK3 and mTORC1 reciprocally
control their activity. Moreover, GSK3 may directly impinge on some
mTORC1 downstream targets.
The first report linking GSK3 with mTORC1 demonstrated an in-
hibition of mTORC1 via phosphorylation of TSC2 by GSK3 at several
amino acidic residues (Thr1329, Ser1333, Ser1337, Ser1341), but only
when TSC2 had been previously phosphorylated at Ser1345 by AMPK
[82]. These findings, obtained in healthy cells (HEK293 cells, murine
fibroblasts, bone marrow stromal cells, cementoblasts, etc.), established
that Wnt/β-catenin signaling enhanced mTORC1-dependent protein
synthesis through the inhibition of GSK3, independently from the
transcriptional activity of β-catenin. Furthermore, they supported a
model where GSK3 and AMPK depend on each other to negatively
regulate mTORC1 activity. Interestingly, an earlier report had docu-
mented that GSK3 interacted with TSC2, as demonstrated by co-im-
munoprecipitation experiments [83]. mTORC1 inhibition via TSC2
phosphorylation by GSK3 was more recently shown to occur also during
neural progenitor development [84].
Subsequent studies, that relied on GSK3 pharmacological inhibitors
and/or overexpression/genetic downregulation of GKS3 isoforms, came
to the conclusion that mTORC1 could be activated by GSK3. However,
these studies did not provide mechanisms explaining how GSK3 could
actually increase mTORC1 activity [85–88]. Nevertheless, since GSK3
Fig. 1. The three classes of mTOR inhibitors. For the details, see the text.
Abbreviations: mTORC1, mechanistic target of rapamycin complex 1; mTORC2,
mechanistic target of rapamycin complex 2; PDK1, phosphoinositide-dependent
kinase 1; PI3K, phosphatidylinositol 3-kinase; TORKIs, mTOR kinase inhibitors.
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inhibitors did not block phosphorylation of mTORC1 downstream tar-
gets in TSC-null cells, it was speculated that GSK3 could act on
mTORC1 via TSC1/TSC2, at least in some settings [86]. A possible
mechanism linking GKS3 with mTORC1 activation is the GSK3β-de-
pendent phosphorylation of Regulatory-associated protein of tor
(Raptor) at Ser859, described by Stretton and coworkers [89]. Raptor is
an mTORC1 adaptor protein that presents substrates to the active site of
mTOR, because it binds the TOR signaling (TOS) motif characterizing
several mTORC1 targets [90]. Either GSK3 pharmacological inhibition
or expression of a mutated (S859A) Raptor, loosened the interactions
between mTOR and Raptor, thereby leading to dephosphorylation of
mTORC1 substrates, such as p70S6K1 (that plays a key role in trans-
lation by phosphorylating substrates such as S6 ribosomal protein
(S6RP) [91]) and uncoordinated-51-like kinase (ULK1, that is critically
involved in autophagy [92]). Importantly, Ser859 Raptor phosphor-
ylation by GSK3 was required for supporting mTORC1-directed amino
acid signaling [89]. More recently, a different group reported that ei-
ther pharmacological inhibition (CHIR-99021, LY2090314) or genetic
downregulation of GSK3β in hepatocellular carcinoma (HCC) cells led
to an activation of AMPK, thereby decreasing mTORC1 activity and
glycolysis, as well as slowing proliferation of cancer cells [93]. These
findings imply that GSK3β exerts a stimulatory effect on mTORC1 in
HCC cells. Indeed, it is known that GSK3β interacts with the AMPK β
regulatory subunit and phosphorylates the AMPK α catalytic subunit at
Thr479. This phosphorylation increases the accessibility of the activa-
tion loop of the AMPKα subunit to phosphatases, thereby inhibiting
kinase activity [94]. Importantly, Fang and coworkers [93] also de-
monstrated that high levels of GSK3β are an independent negative
prognostic factor in HCC patients.
Given these conflicting findings, the role(s) of GSK3 in the regula-
tion of mTORC1 activity might be strictly dependent on the cell type
and/or the cell context. Clearly, these are issues of the utmost im-
portance that urgently need further clarification.
On the other side, mTORC1 is capable of inhibiting GSK3α/β by
regulating their localization to the nucleus. The occurrence of this
phenomenon has been documented in two recently published reports.
The first one, that took advantage of human retinal cells and breast
cancer cells, evidenced how mTORC1 inhibition by rapamycin treat-
ment led to a partial redistribution of GSK3β from the cytoplasm to the
nucleus, thereby ensuing in a reduced expression of both c-Myc and
Snail. Consistently, either AMPK activation or amino acid-deprivation
(i.e. two conditions that result in mTORC1 inhibition) promoted nu-
clear translocation of GSK3β [22].
mTORC1 is capable to downmodulate GSK3α activity, thereby re-
sulting in suppressed phosphorylation of the forkhead/winged helix
family k1 (Foxk1) transcription factor, a critical mediator of mTORC1-
dependent expression of multiple genes associated with glycolysis and
downstream anabolic pathways, mainly via the transcriptional upre-
gulation of Hif-1α [69]. It was shown that these events occur through
an mTORC1-mediated reduction of nuclear GSK3α signaling, whereas,
when mTORC1 is inactivated by rapamycin treatment, Foxk1 is phos-
phorylated by GSK3α at multiple amino acidic residues (Ser402/406/
427/431), binds 14-3-3 proteins, and is excluded from the nucleus. As
we shall see in a subsequent subsection, a mechanism that explains how
mTORC1 regulates GSK3 subcellular distribution has been disclosed
very recently.
Moreover, there is evidence that p70S6K1, a substrate of mTORC1,
is capable of phosphorylating GSK3 at Ser9 in both healthy and cancer
cells, but only in the absence of TSC1 or TSC2. This aberrant phos-
phorylation requires amino acids, is inhibited by rapamycin, leads to
downregulated GSK3 activity, and contributes to growth-factor in-
dependent proliferation of TSC-deficient cells [95]. Furthermore, GSK3
cooperates with mTORC1 by promoting p70S6K1 activity through
phosphorylation at Ser371 within the turn motif of p70S6K1, that
subsequently increases Thr389 phosphorylation by mTORC1 [96].
Last but not the least, GSK3β directly phosphorylates and in-
activates eukaryotic translation initiation factor 4E (eIF4E)-binding
protein 1 (4E-BP1) at Thr37/Thr46, independently of known upstream
kinases of 4E-BP1, including mTORC1, thereby upregulating eIF4E-
dependent protein synthesis [97,98] similarly to mTORC1.
Fig. 2. Circuitries and crosstalks connecting mTORC1 and mTORC2. For the details, see the text. Abbreviations: AMPK, AMP-stimulated protein kinase; 4E-BP1,
eIF4E-binding protein; eIF4E, eukaryotic translation initiation factor 4E; FBXW-7, F-box/WD repeat-containing protein 7; Foxk1, forkhead/winged helix family k1;
GSK3, glycogen synthase kinase 3; Hif-1α, Hypoxia-inducible factor-1α; p70S6K1, 70-kDa ribosomal S6 kinase 1; Raptor, Regulatory-associated protein of tor; Rictor,
Rapamycin-independent companion of tor; Rheb, Ras-homolog enriched in brain; S6RP, S6 ribosomal protein; TSC1, tuberous sclerosis 1; TSC2, tuberous sclerosis 2.
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Regarding mTORC2, GSK3 phosphorylates Rapamycin-insensitive
companion of tor (Rictor) at Thr1695. Rictor is a scaffolding component
important for mTORC2 assembly, stabilization, and activation [2].
Once phosphorylated by GSK3, Rictor interacts with F-box/WD repeat-
containing protein 7 (FBXW-7) that mediates Rictor degradation
through ubiquitination/proteasome-dependent mechanism [99].
Therefore, when GSK3 is inactivated by PI3K/Akt signaling, Rictor
expression levels and mTORC2 assembly are enhanced, thereby in-
creasing mTORC2 activity. However, a positive effect of GSK3β on
mTORC2 activity was reported in mature neurons both in vitro and in
vivo, although no molecular mechanisms underlying this stimulation
were disclosed [87]. The most important signaling circuitries and
crosstalks connecting GSK3 and mTORC1/mTORC2 are summarized in
Fig. 1.
7. Influence of GSK3 on the efficacy of mTOR inhibitors
The impact of mTOR inhibitors, including rapalogs, in the clinic has
been modest at best, as resistance to these drugs is frequently observed
either from the beginning (i.e. innate resistance) or upon long-term
treatment (i.e. evasive or acquired resistance). Therefore, in order to
improve the antineoplastic efficacy of drugs targeting mTOR, there is an
urgent need to further our understanding of the resistance mechanisms
[2].
7.1. GSK3 and its impact on rapamycin sensitivity of cancer cells
The first report pointing out the importance of GSK3 in mediating
some of the anticancer effects of rapamycin dates back to 2014 when
Koo et al. [100] discovered that GSK3 was critically involved in reg-
ulating the degradation of some oncogenic proteins and cancer cell
sensitivity to rapamycin. Indeed, the basal levels of GSK3 activity po-
sitively correlated with the sensitivity of lung cancer cell lines to ra-
pamycin. Consistently, GSK3 pharmacological inhibition antagonized
rapamycin cytostatic effects both in vitro and in vivo, while enforced
activation of GSK3β sensitized cells to rapamycin. Mechanistically, it
was discovered that GSK3 inhibition blocked rapamycin-induced re-
duction of several oncogenic proteins such as cyclin D1, Mcl-1, and c-
Myc, without interfering with the ability of rapamycin to suppress
mTORC1 signaling and protein translation. Interestingly, rapamycin
induces proteasomal degradation of these oncogenic proteins, as evi-
denced by their decreased stability induced by rapamycin and rescue of
their reduced expression by proteasomal inhibition [100]. These results
are in agreement with the findings of Sokolosky et al. [101] who re-
ported a decrease in rapamycin sensitivity when GSK3β activity was
inhibited in MCF-7 cells.
More recently, however, J. Blenis group showed that resistance to
rapamycin in several cancer cell lines was dependent on expression of
Frequently rearranged in advanced T-cell lymphomas protein 1 and 2
(FRAT 1/2) [102]. FRAT 1/2 proteins are well known GSK3-interacting
proteins whose function is to export GSK3 from the nucleus [103]. In
this context, it is important to emphasize that GSK3β constantly shuttles
between the cytoplasm and the nucleus, although it predominantly
localizes to the cytoplasm [104]. Of note, GSK3β lacks a canonical
leucine-rich nuclear export signal (NES), although its nuclear export is
dependent on Chromosomal Maintenance 1 (CRM1), also referred to as
Exportin 1. FRAT 1/2 proteins display a NES, interact with GSK3β, and
carry it out of the nucleus as part of a protein complex [103]. Even
more importantly, FRAT/GSK3β interactions require upregulated PI3K/
Akt/mTORC1 signaling, although the exact mechanisms that control
these molecular interactions are unclear. Nevertheless, when mTORC1
activity is blocked by rapamycin, GSK3β accumulates in the nucleus
where it phosphorylates and inhibits targets important for cancer cell
proliferation and metabolism (KAT5 histone acetyltransferase, c-Myc,
Foxk1). These findings explain some of the anticancer properties of
rapamycin. Consistently, cancer cell lines expressing high levels of
FRAT 1/2 are relatively insensitive to rapamycin, whereas down-
regulation of FRAT 1/2 via siRNA restores rapamycin sensitivity [102].
Interestingly, MCF-7 breast cancer cells express low levels of FRAT 1/2
and are sensitive to rapamycin [102].
In any case, the results by He et al. [102] suggest that FRAT 1/2
expression levels and/or GSK3 subcellular localization might be valu-
able biomarkers for rapamycin sensitivity, and that targeting FRAT 1/2
expression or their interactions with GSK3 may represent valid ther-
apeutic approaches for overcoming rapamycin resistance.
However, there is also evidence showing that a high expression of
GSK3β in the nucleus portends a poorer prognosis in renal cell carci-
noma (RCC) [105,106] and in AML patients [23].
Accordingly, either pharmacological inhibition of GSK3β or re-ex-
pression of miR-199a (that results in GSK3β downregulation) decreased
cancer cell proliferation and survival [105,106]. These data support the
concept that in some cancer settings, nuclear localization of GSK3β
could favor tumor progression rather than inhibiting it.
Rapamycin resistance has also been linked with the capacity of
GSK3 to directly stimulate protein synthesis, thereby bypassing
mTORC1. More specifically, it has been demonstrated that GSK3β in-
teracts with and phosphorylates 4E-BP1 at Thr37/46 residues, thereby
inactivating 4E-BP1 [97]. This phosphorylation increased eIF4E-de-
pendent protein synthesis in both breast and renal cancer cell lines that
were either resistant to rapamycin or that became insensitive after
prolonged exposure [97,98]. Accordingly, rapamycin treatment did not
block proliferation of resistant cancer cell lines, while a GSK3β in-
hibitor (AR-A014418) or GSK3β stable knockdown negatively affected
both translation and cell proliferation [97]. These findings have led to
the hypothesis that GSK3 inhibitors might be combined with rapalogs
for a more efficacious treatment of some types of cancer [97].
In general, the findings reported above point out that is some set-
tings GSK3 is required for rapamycin to display its antineoplastic ef-
fects, whereas in others GSK3, by bypassing mTORC1 activity, is an
important effector of neoplastic cell growth/survival and of resistance
to rapamycin.
7.2. GSK3 involvement in resistance to dual PI3K/mTOR inhibitors
GSK3 is a well-known negative mediator of the Wnt/β-catenin sig-
naling cascade. It has been demonstrated that the Wnt/β-catenin/
GSK3β axis is involved in resistance to mTOR inhibition in human
colorectal carcinoma (CRC) cells. All CRC cell lines that displayed in-
trinsic resistance to the dual PI3K/mTOR inhibitor PF-05212384 (ge-
datolisib) harbored a frameshift mutation (c.465_466insC; H155fs*) in
T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) 7 (TCF7)
[107]. Moreover, resistant cell lines expressed much lower levels of
inactive Ser9 p-GSK3β and higher levels of active Tyr216 p-GSK3β
when compared with the sensitive cell lines. This difference in the GSK3
phosphorylation pattern could be related to the TCF7 frameshift mu-
tation, as siRNA-mediated knockdown of TCF7 decreased Tyr216 p-
GSK3β levels in resistant cells, whereas it increased Ser9 p-GSK3β.
However, it is still unknown how the mutation could impact on GSK3β
phosphorylation. Interestingly, active GSK3β increased the association
of mTOR to Raptor and upregulated mTORC1 activity that was resistant
to gedatolisib [107]. Remarkably, these findings are somehow in
agreement with the report by Stretton and coworkers on the GSK3-
dependent Raptor phosphorylation and enhancement of mTORC1 ac-
tivity [89].
Moreover, downregulation of GSK3β expression in gedatolisib-re-
sistant cells via siRNA-mediated knockdown or pharmacological GSK3β
inhibition by CHIR99021 decreased mTORC1 activity, and rendered the
resistant cell lines sensitive to gedatolisib [107]. Therefore, these
findings suggest that a combined treatment with a GSK3β inhibitor
might be a strategy to overcome intrinsic resistance to PI3K/mTOR-
targeted therapeutics in CRC characterized by high levels of active
GSK3β.
C. Evangelisti, et al. BBA - Molecular Cell Research 1867 (2020) 118635
5
The involvement of GSK3β in the resistance to the dual PI3K/mTOR
inhibitor, NVP-BEZ235, has been documented in human primary GBM
cells chronically exposed to this drug [108]. It is worth pointing out
that PI3K/Akt/mTOR signaling is frequently altered in GBM [109],
however mTOR-targeted therapeutics have failed to improve patient
outcome [110].
In this case, however, combined treatment of GBM cells with NVP-
BEZ235 and the GSK3β selective inhibitor, CHIR99021, conferred re-
sistance to NVP-BEZ235. Moreover, depletion of GSK3β through shRNA
strategy resulted in a marked enhancement of resistance to NVP-
BEZ235. In contrast, knockdown of GSK3α had no effects on drug-re-
sistance [108]. Interestingly, Rictor (an mTORC2 component [90])
knockdown by shRNA prevented the development of resistance to NVP-
BEZ235, thereby suggesting the involvement of mTORC2. Moreover,
the MEK inhibitor AZD6244 decreased resistance to NVP-BEZ235 in
vitro and in vivo, indicating the involvement of MEK/ERK signals. A
mechanism that might explain this type of resistance is outlined in
Fig. 3. It is known that mTORC2 inhibition could lead to MEK/ERK
overstimulation via a feedback activation of the Forkhead box O (FoxO)
family of transcription factors. In particular, it should be considered
that phosphorylation at Ser473 by mTORC2 is required for Akt to exert
its inhibitory effects on FoxO proteins nuclear localization [2]. Indeed,
FoxO phosphorylation by Akt creates docking sites for 14-3-3 proteins.
Once bound to FoxO factors, 14-3-3 proteins enhance FoxO localization
to the cytoplasm, thereby blocking their transcriptional activity [111].
When Akt activity is dampened by a prolonged exposure to NVP-
BEZ235, FoxO factors could upregulate the expression of a variety of
receptor tyrosine kinases (RTKs) [112]. Enhanced RTK expression/ac-
tivity then leads to activation of the MEK/ERK pathway, as reported by
another group [113]. It is still controversial whether ERK could directly
phosphorylate GSK3β. However, available evidence indicates that ERK
associates with and phosphorylates GSK3β at Thr43, thereby priming
GSK3β for subsequent phosphorylation at Ser9 by p90RSK (a down-
stream target of ERK). These two phosphorylation events result in
GSK3β inactivation [114] (Fig. 3).
Importantly, among RTKs whose expression is enhanced via FoxO
factors, epidermal growth factor receptor (EGFR), human epidermal
growth factor receptor (HER) 2, and HER3 play key roles in human
GBM cell pathophysiology [115]. Furthermore, the MEK/ERK/p90RSK/
GSK3β axis is a common signal, as it was observed in a variety of
human tumors, including breast, stomach, kidney, and liver cancer
[114].
Laks and coworkers [108] were also able to identify microtubule-
associated protein (MAP)1B, as a downstream target of MEK/ERK/
p90RSK/GSK3β signaling that led to the development of acquired re-
sistance to NVP-BEZ235 in human GBM cells. Indeed, either GSK3β
pharmacological inhibition or depletion of GSK3β via shRNA strategy,
decreased the levels of p-MAP1B, a GSK3β substrate. However, GSK3β-
dependent phosphorylation had been previously mapped to the
Ser1260 and Thr1265 residues of MAP1B [116], while Laks and et al.
[108] identified Thr1270 as the hyperphosphorylated residue. There-
fore, it could be hypothesized that the enhanced phosphorylation of
MAP1B could be due either to the upregulation of a protein kinase or
the downregulation of a protein phosphatase that both are controlled
via the MEK/ERK/p90RSK/GSK3β axis. Whichever the case, the final
result is the appearance of evasive resistance to NVP-BEZ235 (Fig. 3). It
is still unknown how MAP1B could determine the development of re-
sistance to this dual PI3K/mTOR inhibitor. It should be considered,
however, that MAP1B is involved in several signaling pathways, in
addition to its canonical roles in the regulation of actin microfilament
and microtubule polymerization [117]. Of note, GSK3β/MAP1B-de-
pendent drug-resistance was also observed in GBM cells treated with
rapamycin, consistently with ability of this drug to dampen mTORC2
activity in some cancer settings [108]. These findings are extremely
Fig. 3. GSK3β is involved in development of evasive resistance in human glioblastoma cells. Prolonged exposure to mTOR inhibitors (NVP-BEZ235, rapamycin)
dampens mTORC2 activity and allows FoxO transcription factors translocation to the nucleus (1); once in the nucleus, FoxO factors upregulate the expression of
genes coding for RTK (EGFR, HER2, HER3) (2); enhanced RTK expression/activity increases signaling along the MEK/ERK/p90RSK axis, thereby inhibiting GSK3β
(3); as a consequence, the levels of Thr1270 p-MAP1B somehow increase (4) and resistance to mTOR-targeting drugs is induced (5). Abbreviations: EGFR, epidermal
growth factor receptor; ERK, extracellular signal-regulated kinase; FoxO, Forkhead box O; Grb2, Growth factor receptor bound protein 2; GSK3β, glycogen synthase
kinase 3β; HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor receptor 3; MAP1B, microtubule-associated protein 1B; MEK,
mitogen-activated protein kinase kinase; mTORC2, mechanistic target of rapamycin complex 2; p90RSK, 90-kDa ribosomal S6 kinase; Ras, Rat sarcoma viral
oncogene homolog; RTK, receptor tyrosine kinase; Shc, Src homology 2 domain containing; Sos, Son-of-sevenless homolog;
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interesting in that they provide a link between mTORC2 inhibition,
MEK/ERK activation, and a GS3Kβ-mediated mechanism of resistance
to therapeutics targeting mTOR. Nevertheless, it should be pointed out
that activation of GSK3β in GMB correlated inversely with patient
outcome as an independent prognostic factor [118]. Therefore, inhibi-
tion of GSK3β might well enhance the efficacy of therapeutics targeting
mTOR while negatively influencing at the same time other aspects of
GBM pathophysiology.
7.3. GSK3 impact on treatment with TORKIs
In general, GSK3 seems to play a dual role also in influencing cancer
cell sensitivity to TORKIs.
On one side, Koo et al. [119] demonstrated that GSK3 activity is a
critical determinant for TORKIs in vitro efficacy as anticancer ther-
apeutics, as documented via either pharmacologic inhibition or genetic
attenuation of GSK3. The negative effects of GSK3 pharmacological
inhibition on sensitivity to TORKIs, were observed also in vivo, through
the use of human non-small-cell lung carcinoma (NSCLC) xenografted
in nude mice. Conversely, expression of a constitutively active form of
GSK3β sensitized neoplastic cells to the inhibitors. Of note, higher basal
levels of GSK3 activity in a panel of human lung cancer cell lines cor-
related with more efficacious responses to TORKIs. Mechanistically, it
was discovered that TORKIs decreased cyclin D1 expression levels in a
GSK3β-dependent manner, independently from their effects on sup-
pressing mTORC1-dependent translation. Indeed, mTORC2 inhibition
triggered proteasome-mediated cyclin D1 degradation, that was dam-
pened by silencing expression of F-box protein 4 (FBX4), a component
of the S-phase kinase-associated protein 1 (SKP1)-cullin 1-F-box protein
(SCF) E3 ligase complex [119,120].
More recently, however, it has been shown that GSK3 could act as
the driving force behind the development of evasive resistance to
TORKIs [121]. In this respect, it should be considered that both
mTORC1 and mTORC2 are involved in regulating glucose, amino acid,
lipid, and nucleotide metabolism in cancer cells [122]. Although neo-
plastic cells usually engage in large scale aerobic glycolysis, as first
reported by Otto Warburg in the 1920s [123], it is now equally clear
that several types of cancers rely on glutamine catabolism (glutami-
nolysis) for energy production to satisfy their demand of accelerated
proliferation and growth [124]. Glutaminase (GLS) is the enzyme that
catalyzes the lysis of glutamine to glutamate. Two isoforms of GLS exist,
GLS1 and GLS2 [125]. Importantly, evidence shows that glutaminolysis
is associated with the enhanced activity of c-Myc [126], a target of
GSK3 signaling. C-Myc-driven cancers are characterized by heightened
uptake of nutrients, increased glycolysis and glutaminolysis, as well as
by enhanced fatty acid and nucleotide synthesis [127,128]. Moreover,
recent evidence indicates that c-Myc-dependent metabolic rewiring of
cancer cells allows them to react and adapt to a variety of cues and
stresses in their microenvironment [129].
Therefore, a better understanding of the complexity of c-Myc-
mediated metabolic reprogramming in tumors as well as how c-Myc
cooperates with other metabolic drivers, such as mTORC1 and
mTORC2, may provide translational opportunities for cancer therapy
using small drug molecules.
Lung squamous cell carcinoma (SCC) is a very aggressive subset of
NSCLC, characterized by prognosis poorer than lung adenocarcinoma.
Lung SCC cells utilize large amounts of glucose to meet their metabolic
needs and display activation of PI3K/Akt/mTOR signaling [130].
Momcilovic and coworkers [121] were able to identify GSK3 as the
molecular switch that reprograms tumor metabolism from mTORC1-
dependent glycolysis to glutaminolysis in response to prolonged treat-
ment of lung SCC cells with MLN0128 (also known as TAK-228), an
investigational-grade TORKI [131].
MLN0128 effectively inhibited mTORC1 activity and suppressed
glucose metabolism, however it failed to dampen in vivo tumor growth
in a murine model of lung SCC displaying a high dependence on
glutamine [121,130]. Using the RH2 human lung SCC line, it was then
demonstrated that both MLN0128 and rapamycin suppressed glucose
uptake while concomitantly increasing glutamine uptake in vitro. Si-
milar findings were obtained with xenografted RH2 cells. Importantly,
it was observed that lung SCC cancers, that were resistant to MLN0128
treatment in mice, had increased levels of Thr308 p-Akt. This phe-
nomenon has been reported in other cancer types, for example in
pancreatic carcinoma and AML treated with TORKIs, where it was
shown to be dependent on enhanced FoxO/RTK/PI3K/PDK1 signaling
[132,133]. High levels of Thr308 p-Akt led to inactivation of GSK3 that
resulted in an increased stability of both c-Myc and c-Jun (hyperpho-
sphorylated at Ser73), two proteins critically involved the regulation of
GLS1 expression levels. The increase in c-Myc and c-Jun is related to the
fact that active GSK3 facilitates the degradation of these oncoproteins
via E3 ubiquitin ligases [134,135]. Of note, it was also demonstrated
that p-GSK3 levels were a predictive marker of MLN0128 sensitivity in
human patient-derived xenografts (PDXs) of lung SCCs, and that the
GLS inhibitor CB-839 overcame metabolic reprogramming and re-
sistance to MLN0128 in human lung SCC cell lines and PDXs [121].
Furthermore, Momcilovic and coworkers [121] discovered in
human lung SCC, head and neck squamous cell carcinoma, and osteo-
sarcoma a distinctive metabolic signature that predicted outcome and
suggested how neoplasias relying primarily on aerobic glycolysis may
be responsive to a combinatorial treatment consisting of MLN0128 and
CB-839. Such a metabolic signature is defined by a positive staining for
glucose transporter 1 (GLUT1), the glutamine transporter solute carrier
family 1 member 5 (SLC1A5), p-4EBP1, p-GSK3, and nuclear Ser73 p-c-
Jun. Overall, these findings emphasize the relevance of GSK3 and GLS1
as drivers of compensatory glutamine metabolism that results in re-
sistance to TORKIs in some cancer types. They also suggest a rational
combination therapy, not based on GSK3 inhibition, that has the po-
tential to overcome resistance to TORKIs.
8. Concluding remarks and future perspectives
Aberrant activation of the PI3K/Akt/mTOR pathway has been ob-
served in multiple cancers. However, the efficacy of FDA- and EMA-
approved rapalogs is extremely limited, as drug-resistance has been
observed since the beginning of treatment or developed upon prolonged
exposure. Resistance has been observed also during clinical trials of
dual PI3K/mTOR and TORKIs. Mechanisms of clinical resistance to
inhibitors targeting mTOR are unclear [2]. Therefore, understanding
and overcoming resistance to mTOR-targeting drugs in neoplastic pa-
tients remains a major objective in cancer therapy.
The roles of GSK3 in cancer are paradoxical and enigmatic. This
pleiotropic kinase interacts with major multiple signaling networks and
for this very reason, it has emerged as a potential target in some human
disorders. Aberrant GSK-3 signaling has been implicated in the devel-
opment and progression of several types of malignant tumors, however
therapeutic intervention has been compounded by the fact that GSK3
paralogs can function as either cancer promoters or suppressors based
on the cell-type and context.
As summarized in this review, GSK3 and mTORC1/mTORC2 are
interconnected by complex, multiple circuitries that have been only
recently become to be unraveled. It is evident that, in some cancer
settings, GSK3 is a key player involved in the development of resistance
to mTOR inhibition. Therefore, from a theoretical point of view, GSK3
inhibitors may be combined with mTOR inhibitors for overcoming
drug-resistance. Nevertheless, in other cancer types GSK3 activity
seems to be important for mTOR inhibitors to fully unleash their anti-
neoplastic potential, hence the mixed actions of GSK3 make it difficult
to harness potential therapeutic interventions. In this case, GSK3 “ac-
tivators” might be considered, however, at present no specific GSK3
activators are under development [71].
The differences in the roles played by GSK3 in various types of
cancer may have hampered the development of GSK3-targeted
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therapeutics for antineoplastic therapy. However, further investigation
of the mechanisms underlying the opposite actions of GSK3 in different
types of tumors, also related to mTOR inhibition, should provide op-
portunities to better understand the processes controlled by GSK3 and
to identify those that may safely benefit from administration of selec-
tive drugs. Moreover, this kind of studies could provide insights toward
other molecules, controlled by GSK3, that would serve as targets more
amenable to a therapeutic intervention, as we have seen in the works of
Momcilovic et al. [121] and He et al. [69,102]. These studies could also
lead to the development of substrate-competitive GSK3 inhibitors with
a high specificity for one of the two paralogs, as already demonstrated
in some studies [136–138].
Although the role of GSK3 in tumors is paradoxical, there is sub-
stantial evidence to indicate that modulating GSK3 activity is a rational
strategy for the treatment of cancer, also for increasing the efficacy of
mTOR-targeting agents. Evaluation of the GSK3 expression/phosphor-
ylation profiles, together with the assessment of the activation/in-
activation of upstream signaling kinases that regulate GSK3, may be
useful biomarkers in selecting patients who can maximally benefit from
treatment with GSK3 activity modulators [139].
Last but not the least, a critical step will be to gain a more com-
prehensive understanding of the reciprocal interactions between GSK3
and mTOR within cells of the tumor microenviroment, including im-
mune and inflammatory cells, as drugs targeting mTOR and GSK3 could
have a major impact on them, thereby influencing clinical response
[49,140–142].
In conclusion, despite its enigmatic roles, reversing the activation/
inactivation status of GSK3, with minimal detrimental effects on
healthy cells, appears to be a pragmatic approach to harness this kinase
and to improve the efficacy of mTOR inhibitors in cancer patients.
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